Phathom Pharmaceuticals Inc.

PHAT | NASDAQ

Price Alert Chart Builder DCF Calculator

$7.45

-$0.03 (-0.40%)

At close: Sep 21, 2026, 4:00 PM ET

$7.45

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.40%

(1D)

Rating

Updated: Aug 12, 2026

31.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $602.71M

1D Range

7.37 7.52

52W Range

7.35 18.31

Valuation (TTM)

PE -5.82

PB -1.75

EV/EBITDA -11.51

Valuation (NTM)

Forward PE 10.61

Forward PEG 0.03

Price Target $17.60

Cash Flow

FCF Yield -6.1%

SBC Adj. FCF Yield -10.6%

SBC Impact -74.3%

Margins

Gross Margin 82.9%

Operating Margin -17.0%

FCF Margin -15.3%

Growth (CAGR)

Revenue 3Y | 5Y 94.8% | 81.6%

Dil EPS 3Y | 5Y 51.8% | 15.5%

FCF 3Y | 5Y 51.2% | 4.6%

Returns

ROA -30.3%

ROE 25.7%

ROIC -23.4%

Financial Health

Net Cash

$179.95M

Current Ratio 1.92

Interest Coverage -0.64

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company i...

Sector Healthcare

Industry Biotechnology

Employees 371

IPO Date Oct 24, 2019

Website www.phathompharma.com

Fiscal Year January - December

Full Company Profile

Latest News

5 months ago · globenewswire.com

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update.

8 months ago · globenewswire.com

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on Thursday, February 12, 2026, at 11:30 am EST.

Earnings

Next Earnings

Oct 29, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$20

Upside

+168.46%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞